Trevena Inc. (TRVN)

Name: Trevena Inc. (TRVN) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Trevena Inc. (TRVN)

Stock Card

$0.00

$0.00 (0.00%)

As on 25-Aug-2026 09:30EDT

Market cap

$0 Mln

Revenue (TTM)

$1 Mln

P/E Ratio

P/B Ratio

0.4

Div. Yield

0 %

Trevena (TRVN) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 0.00 High: 0.00

52 Week Range

Low: 0.00 High: 0.90

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-10.1 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

0.2
Debt to Equity

-1.4
Book Value

$--
EPS

$-35.8
Face value

--
Shares outstanding

863,788

10 Years Aggregate

CFO

$-447.81 Mln

EBITDA

$-490.56 Mln

Net Profit

$-508.41 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Trevena (TRVN)	-91.7	-90.9	-90.9	-99.6	-96.5	-93.3	-78.4
BSE Sensex^*	-8.8	1.6	1.6	-4.4	6.0	6.7	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 25-Aug-2026 | *As on 27-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020	2019
Trevena (TRVN)	-99.2	-91.6	-49.5	-90.2	-72.8	154.5	95.6
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Trevena (TRVN)	0.0	0.0	0.6	-34.0	-3,005.9	--	--	0.4
Arrowhead Pharmaceuticals (ARWR)	89.1	12,304.7	669.5	-320.0	-0.8	-71.1	--	26.4
Ascendis Pharma A/S - ADR	250.3	16,614.0	1,054.4	755.9	5.7	--	19.4	10.1
Cytokinetics Inc (CYTK)	79.2	10,682.6	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	56.1	13,400.0	2,435.9	860.6	31.0	43	17	7.3
Halozyme Therapeutics (HALO)	107.1	12,277.1	1,663.7	413.6	36.3	430	31.2	83.9
Madrigal Pharmaceuticals (MDGL)	538.9	11,938.8	1,283.9	-325.1	-19.0	-57.7	--	22.9
Medpace Holdings (MEDP)	619.1	17,326.2	2,782.3	491.5	21.1	110.1	36.5	39.4
Praxis Precision MedicinesÂ Inc (PRAX)	377.4	10,496.2	0.0	-339.1	--	-30.6	--	7.6
Protagonist Therapeutics (PTGX)	151.5	9,985.8	282.0	82.9	-28.6	11.4	147	11.6

Shareholding Pattern

View Details

About Trevena (TRVN)

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G... protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania. Read more

President, CEO & Chairman

Ms. Carrie L. Bourdow
President, CEO & Chairman

Ms. Carrie L. Bourdow
Headquarters

Chesterbrook, PA
Website

https://www.trevena.com

FAQs for Trevena (TRVN)

What is the current share price of Trevena Inc (TRVN) Today?

The share price of Trevena Inc (TRVN) is $0.00 (NASDAQ) as of 25-Aug-2026 09:30 EDT. Trevena Inc (TRVN) has given a return of -96.48% in the last 3 years.

What is the current PB & PE ratio of Trevena Inc (TRVN)?

Since, TTM earnings of Trevena Inc (TRVN) is negative, P/E ratio is not available.
The P/B ratio of Trevena Inc (TRVN) is 0.36 times as on 21-Aug-2026, a 93 discount to its peers’ median range of 5.35 times.

PE & PB ratio at the end of financial year.